Aug 26 (Reuters) - Drugmaker Emergent BioSolutions

said on Monday that it would reduce its workforce in

Lansing, Michigan, by up to 70 roles as part of its ongoing

restructuring efforts.

The Gaithersburg, Maryland-based company has been cutting

costs and pivoting away from its contract manufacturing business

due to sluggish demand and a focus on driving sales growth for

its opioid overdose reversal drug Narcan and other branded

drugs.

In May, Emergent cut about 300 jobs and shut down a drug

substance manufacturing facility in Baltimore, Bayview and a

drug product facility in Rockville, Maryland.

The Lansing site serves as a hub for its drug substance

manufacturing capabilities, as well as other critical projects.

The affected roles were related to manufacturing and site

operations, and about 155 employees will remain at the plant

that primarily manufactures anthrax vaccines, BioThrax and

Cyfendus for the U.S. government, the company told Reuters.